AIM ImmunoTech's Ampligen trial in COVID-19 'long haulers' proceeds

 

• AIM ImmunoTech (NYSEMKT:AIM) gains 13% in premarket after Institutional Review Board's (IRB) green signal to commence enrollment in post-COVID-19 "Long Hauler" portion of the active AMP-511 Expanded Access Program, evaluating Ampligen.
• The program is authorized to enroll up to 100 active trial participants, 20 of whom may be Long Haulers.
• The company in October announced that the myalgic encephalomyelitis / chronic fatigue syndrome ((ME/CFS)) trial received IRB approval to include patients previously diagnosed with COVID-19, but who now demonstrate post-acute infection chronic fatigue-like symptoms.
• Ampligen is AIM's TLR3 agonist immune-system modulator. It is approved in Argentina as the world's first therapy for severe Chronic Fatigue Syndrome and the company says it is the only late-stage drug in the U.S. development pipeline for ME/CFS.
• https://seekingalpha.com/news/3647334-aim-immunotechs-ampligen-trial-in-covidminus-19-long-haulers-moves-forward